Cabazitaxel and prednisone as second-line therapy of metastatic, castration-resistant prostate cancer

Bagi R.P. Jana

    Research output: Contribution to journalArticle

    1 Scopus citations

    Abstract

    A novel taxane improves progression-free and overall survival of patients with metastatic, hormone-refractory prostate cancer after failure of docetaxel therapy.

    Original languageEnglish (US)
    Pages (from-to)540-542
    Number of pages3
    JournalCommunity Oncology
    Volume7
    Issue number12
    DOIs
    StatePublished - Dec 2010

    ASJC Scopus subject areas

    • Hematology
    • Oncology

    Fingerprint Dive into the research topics of 'Cabazitaxel and prednisone as second-line therapy of metastatic, castration-resistant prostate cancer'. Together they form a unique fingerprint.

  • Cite this